Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Conditions:   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma Interventions:   Biological: Daratumumab;   Drug: Ibrutinib Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials